While the situation in 2020 was not as bad as in some other countries, Japan like the rest of the world has been grappling with the coronavirus outbreak. In the pharma policy and regulatory sphere, this meant recognizing the situation, adapting, and enacting change where impactful.
The most obvious response came in public declarations from the country’s main regulatory bodies, the Ministry of Health, Labour and...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?